GeneDx Holdings (WGS) Superinvestor holders
12 of the superinvestors we track hold GeneDx Holdings (WGS) in their latest 13F filings, $477M in total.
Summary
The largest holder is Keith Meister (Corvex Management), with $328M, 10.2% of the portfolio.
In their latest quarter: 1 opened a new position, 8 added, 3 trimmed.
Who holds it
Each investor's latest 13F filing, largest stake first. What a 13F shows.
| Investor | Last change | Shares | Value | % of portfolio | Filed for |
|---|---|---|---|---|---|
| Keith Meister Corvex Management |
Added | 4,784,570 | $328M | 10.2% | Q2 2026 |
| Cathie Wood ARK Investment Management |
Added | 1,610,189 | $111M | 0.7% | Q2 2026 |
| Paul Tudor Jones Tudor Investment Corp |
Added | 108,839 | $7M | 0.0% | Q2 2026 |
| Alger Fred Alger Management |
Trimmed | 108,527 | $7M | 0.0% | Q2 2026 |
| Steve Cohen Point72 Asset Management |
Added | 97,300 | $7M | 0.0% | Q2 2026 |
| Matthew Halbower Pentwater Capital Management |
New position | 82,500 | $6M | 0.0% | Q2 2026 |
| Chuck Royce Royce Investment Partners |
Trimmed | 39,640 | $3M | 0.0% | Q3 2026 |
| David Shaw D. E. Shaw & Co. |
Added | 38,877 | $3M | 0.0% | Q2 2026 |
| Cliff Asness AQR Capital Management |
Added | 29,172 | $2M | 0.0% | Q2 2026 |
| Alan Howard Brevan Howard |
Added | 28,172 | $2M | 0.0% | Q2 2026 |
| Two Sigma Two Sigma Investments |
Added | 10,684 | $733,457 | 0.0% | Q2 2026 |
| Ensign Peak Ensign Peak Advisors |
Trimmed | 1,550 | $106,408 | 0.0% | Q2 2026 |
Holders by quarter
| Quarter | Superinvestors holding it |
|---|---|
| Q2 2026 | 12 |
| Q1 2026 | 17 |
| Q4 2025 | 16 |
| Q3 2025 | 16 |
| Q2 2025 | 14 |
| Q1 2025 | 17 |
| Q4 2024 | 15 |
| Q3 2024 | 14 |
Questions about GeneDx Holdings
Which superinvestors own GeneDx Holdings?
12 of the superinvestors we track hold GeneDx Holdings (WGS) in their latest 13F filings, $477M in total. Keith Meister, Cathie Wood, Paul Tudor Jones, Alger, Steve Cohen, Matthew Halbower.
Who is the largest superinvestor holder of WGS?
The largest holder is Keith Meister (Corvex Management), with $328M, 10.2% of the portfolio.
From GeneDx Holdings's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.